Navigating New Data With Next-Generation BTK Inhibitors in CLL

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

Adrian Wiestner, MD, PhD, sheds light on resistance mutations in patients with chronic lymphocytic leukemia who were treated with acalabrutinib.

Alessandra Ferrajoli, MD, discusses the rationale for, and findings from, a cumulative review of hypertension in patients with chronic lymphocytic leukemia and other hematologic malignancies who received acalabrutinib.

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.